Charpiat B[au] - Search Results

Year	Number of Results
1994	1
1996	3
1998	1
2001	2
2002	2
2003	1
2004	1
2005	3
2006	3
2007	3
2008	3
2009	4
2010	4
2011	3
2012	6
2013	6
2014	8
2015	7
2016	7
2017	4
2018	5
2019	2
2020	3
2021	7
2022	2

1

Green tea and hepatoxicity: Two case reports.

Percevault S, Charpiat B, Lebossé F, Mabrut JY, Vial T, Colom M. Percevault S, et al. Among authors: charpiat b. Therapie. 2021 Oct 23:S0040-5957(21)00209-2. doi: 10.1016/j.therap.2021.10.004. Online ahead of print. Therapie. 2021. PMID: 34776253 No abstract available.

2

[Emergent adverse effects of proton pump inhibitors].

Bourne C, Charpiat B, Charhon N, Bertin C, Gouraud A, Mouchoux C, Skalli S, Janoly-Dumenil A. Bourne C, et al. Among authors: charpiat b. Presse Med. 2013 Feb;42(2):e53-62. doi: 10.1016/j.lpm.2012.09.016. Epub 2012 Dec 10. Presse Med. 2013. PMID: 23237784 Review. French.

3

Curbing proton pump inhibitor overprescribing: Multifaceted strategies in an academic hospital.

Veremme L, Janoly-Dumenil A, Charpiat B. Veremme L, et al. Among authors: charpiat b. J Clin Pharm Ther. 2021 Aug;46(4):1041-1045. doi: 10.1111/jcpt.13395. Epub 2021 Feb 24. J Clin Pharm Ther. 2021. PMID: 33629438

4

Erythromycin as a prokinetic agent: risk factors.

Berthet S, Charpiat B, Mabrut JY. Berthet S, et al. Among authors: charpiat b. J Visc Surg. 2010 Apr;147(2):e13-8. doi: 10.1016/j.jviscsurg.2010.06.001. Epub 2010 Jul 23. J Visc Surg. 2010. PMID: 20655290 Free article. Review.

5

Consequences of renal failure on non-renal clearance of drugs.

Lalande L, Charpiat B, Leboucher G, Tod M. Lalande L, et al. Among authors: charpiat b. Clin Pharmacokinet. 2014 Jun;53(6):521-32. doi: 10.1007/s40262-014-0146-1. Clin Pharmacokinet. 2014. PMID: 24861189 Review.

6

Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?

Charpiat B, Bleyzac N, Tod M. Charpiat B, et al. Clin Drug Investig. 2020 Oct;40(10):897-899. doi: 10.1007/s40261-020-00963-x. Clin Drug Investig. 2020. PMID: 32779119 Free PMC article. Review.

7

[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].

Bensalah N, Garcia S, Rose FX, Bedouch P, Conort O, Juste M, Roubille R, Allenet B, Tod M, Charpiat B. Bensalah N, et al. Among authors: charpiat b. Prog Urol. 2017 Apr;27(5):275-282. doi: 10.1016/j.purol.2017.02.003. Epub 2017 Mar 30. Prog Urol. 2017. PMID: 28365198 Review. French.

8

[Contribution of a hospital pharmacy team to critical care of patients infected with SARS-CoV-2].

Besson C, Chareyre S, Kirouani N, Jean-Jean S, Bretagnolle C, Henry A, Leboucher G, Charpiat B. Besson C, et al. Among authors: charpiat b. Ann Pharm Fr. 2021 Jul;79(4):473-480. doi: 10.1016/j.pharma.2021.01.007. Epub 2021 Jan 29. Ann Pharm Fr. 2021. PMID: 33516718 Free PMC article. French.

9

CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions.

Vo HT, Charpiat B, Chanoine S, Juste M, Roubille R, Rose FX, Conort O, Allenet B, Bedouch P; Working Group “Valorization of Pharmacist Interventions” of the French Society of Clinical Pharmacy. Vo HT, et al. Among authors: charpiat b. Eur J Hosp Pharm. 2021 Jul;28(4):193-200. doi: 10.1136/ejhpharm-2020-002642. Epub 2021 Apr 21. Eur J Hosp Pharm. 2021. PMID: 33883205

10

Potassium overdose using an oral solution: Potassium element expressed in grams as a packaging flaw contributing to medication error.

Charpiat B, Veremme L, Duriez B, Sigal A. Charpiat B, et al. Ann Pharm Fr. 2021 May;79(3):286-290. doi: 10.1016/j.pharma.2020.10.008. Epub 2020 Oct 21. Ann Pharm Fr. 2021. PMID: 33098873

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results